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Summary
Background The COPD Assessment Test (CAT) is responsive to change in patients with chronic obstructive pulmonary 
disease (COPD). However, the minimum clinically important diﬀ erence (MCID) has not been established. We aimed 
to identify the MCID for the CAT using anchor-based and distribution-based methods.
Methods We did three studies at two centres in London (UK) between April 1, 2010, and Dec 31, 2012. Study 1 
assessed CAT score before and after 8 weeks of outpatient pulmonary rehabilitation in patients with COPD who 
were able to walk 5 m, and had no contraindication to exercise. Study 2 assessed change in CAT score at discharge 
and after 3 months in patients admitted to hospital for more than 24 h for acute exacerbation of COPD. Study 3 
assessed change in CAT score at baseline and at 12 months in stable outpatients with COPD. We focused on 
identifying the minimum clinically important improvement in CAT score. The St George’s Respiratory 
Questionnaire (SGRQ) and Chronic Respiratory Questionnaire (CRQ) were measured concurrently as anchors. 
We used receiver operating characteristic curves, linear regression, and distribution-based methods (half SD, SE 
of measurement) to estimate the MCID for the CAT; we included only patients with paired CAT scores in the 
analysis.
Findings In Study 1, 565 of 675 (84%) patients had paired CAT scores. The mean change in CAT score with pulmonary 
rehabilitation was –2·5 (95% CI –3·0 to –1·9), which correlated signiﬁ cantly with change in SGRQ score (r=0·32; 
p<0·0001) and CRQ score (r=–0·46; p<0·0001). In Study 2, of 200 patients recruited, 147 (74%) had paired CAT 
scores. Mean change in CAT score from hospital discharge to 3 months after discharge was –3·0 (95% CI –4·4 to –1·6), 
which correlated with change in SGRQ score (r=0·47; p<0·0001). In Study 3, of 200 patients recruited, 164 (82%) had 
paired CAT scores. Although no signiﬁ cant change in CAT score was identiﬁ ed after 12 months (mean 0·6, 
95% CI –0·4 to 1·5), change in CAT score correlated signiﬁ cantly with change in SGRQ score (r=0·36; p<0·0001). 
Linear regression estimated the minimum clinically important improvement for the CAT to range between 
–1·2 and –2·8 with receiver operating characteristic curves consistently identifying –2 as the MCID. Distribution-
based estimates for the MCID ranged from –3·3 to –3·8.
Interpretation The most reliable estimate of the minimum important diﬀ erence of the CAT is 2 points. This estimate 
could be useful in the clinical interpretation of CAT data, particularly in response to intervention studies.
Funding Medical Research Council and UK National Institute of Health Research.
Introduction
The COPD Assessment Test (CAT) is a simple, eight item, 
health status instrument for patients with chronic 
obstructive pulmonary disease (COPD), which is highly 
practical,1 has good psychometric properties, and has been 
shown to be responsive to pulmonary rehabilitation and 
recovery from exacerbation.2–8 A decrease in CAT score 
represents an improvement in health status, whereas an 
increase in CAT score represents a worsening in health 
status. The CAT has been incorporated into the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
combined assessment of COPD as a means of establishing 
a symptomatic threshold to guide initiation of regular 
pharmacological treatment.9 Because it takes only 2–3 min 
to complete, the CAT has practical advantages over longer-
established health status questionnaires such as the St 
George’s Respiratory Questionnaire (SGRQ) and the 
Chronic Respiratory Questionnaire (CRQ).
The minimum clinically important diﬀ erence (MCID) 
is the smallest change in score that patients perceive as 
beneﬁ cial or detrimental, and is useful to aid the 
clinical interpretation of health status data, particularly 
in response to intervention. By contrast with other 
health status questionnaires commonly used in COPD 
such as the SGRQ and CRQ,10–12 to our knowledge the 
MCID of the CAT has not been described.
We aimed to estimate the MCID for the CAT using a 
range of anchor-based and distribution-based methods 
in three diﬀ erent clinical scenarios: response to 
pulmonary rehabilitation, recovery after admission to 
hospital for acute exacerbation of COPD, and 
longitudinal change with time. We postulated that 
the CAT score would improve with pulmonary 
rehabilitation and recovery from admission to hospital 
(ie, a decrease in CAT score), but worsen with time in 
stable patients (ie, an increase in CAT score), and that 
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change in CAT score would correlate signiﬁ cantly with 
change in other  well-established COPD health status 
questionnaires.
Methods
Participants
In Study 1, we recruited stable patients with COPD from 
the Hareﬁ eld Pulmonary Rehabilitation Unit (Hareﬁ eld 
Hospital, London, UK). Inclusion criteria included a 
diagnosis of COPD, ability to walk 5 m, and no 
contraindication to exercise.13 For Study 2, we recruited 
patients who had an acute exacerbation of COPD 
diagnosed by a physician and an admission longer than 
24 h to acute wards at Hillingdon Hospital (London, UK). 
In Study 3, we recruited stable patients with COPD from 
outpatient clinics at Hareﬁ eld Hospital; patients were 
deemed stable if they had not had an exacerbation in the 
4 weeks before the baseline measurement. Patients were 
not excluded from Study 3 if they had an excerbation 
during the 12 month follow-up period. Age 35 years or 
older was an inclusion criterion for all studies. Patients 
unable to read or understand English were excluded 
from all studies. All participants gave written informed 
consent and all studies received local ethics committee 
approval.
Procedures
Study 1 assessed response of the CAT to pulmonary 
rehabilitation. We measured the CAT, SGRQ, and CRQ 
before and after an 8 week outpatient pulmonary 
rehabilitation programme, consisting of twice weekly 
supervised exercise and education sessions.6,12,14 We 
measured the incremental shuttle walk, ﬁ ve-repetition 
sit-to-stand, and 4 m gait speed to assess change in 
physical performance.15–17 Patients were kept masked to 
their performance and were asked to rate their change in 
health status after pulmonary rehabilitation using an 
adapted ﬁ ve point Global Rating of Change 
Questionnaire (GRCQ).18 Patients were asked to classify 
how they felt after pulmonary rehabilitation according to 
ﬁ ve responses: “1: much better”; “2: a little better”; 
“3: no change”; “4: a little worse” and “5: much worse”. 
Data from 255 of the 565 patients in Study 1 have been 
used as a comparator group in a previous study.19
Study 2 assessed change in CAT score after admission 
to hospital for acute exacerbation of COPD. Forced 
expiratory volume in one second (FEV1), CAT, SGRQ, and 
4 m gait speed were measured on the day of hospital 
discharge and about 3 months later.
Study 3 assessed longitudinal change in CAT score 
with time. Patients with COPD attending outpatient 
respiratory clinics were asked to complete FEV1, 
incremental shuttle walk, 4 m gait speed, CAT, and 
SGRQ, and again at 12 months.
Statistical analysis
Study 1 was a pragmatic observational study in which we 
aimed to prospectively recruit a minimum of 500 patients 
with paired CAT measurements. We anticipated 
25% dropout on the basis of our experience with the 
pulmonary rehabilitation programme and therefore 
Baseline Change after pulmonary 
rehabilitation
p value
Mean age (years [SD]) 70 (9) ·· ··
Sex
Men 327 (58%) ·· ··
Women 238 (42%) ·· ··
Mean BMI (kg/m² [SD]) 27·6 (6·0) ·· ··
FEV1 (% predicted) 47·6 (45·9 to 49·3) ·· ··
MRC 3·4 (3·3 to 3·5) ·· ··
ISW (m) 210 (199 to 222) 53 (47 to 59) <0·0001
5STS (s) 15·3 (14·6 to 16·0) –2·4 (–3·9 to –1·9) <0·0001
4MGS (m s–1) 0·90 (0·88 to 0·93) 0·07 (0·06 to 0·08) <0·0001
SGRQ
Total 51·0 (49·3 to 52·6) –5·0 (–6·1 to –3·8) <0·0001
Symptoms 64·7 (62·7 to 66·6) –3·8 (–5·4 to –2·3) <0·0001
Activities 68·8 (66·7 to 70·8) –3·7 (–5·3 to –2·1) <0·0001
Impact 36·5 (34·7 to 38·3) –5·9 (–7·2 to –4·5) <0·0001
CRQ
Total 75·9 (74·1 to 77·7) 14·5 (11·1 to 17·9) <0·0001
Dyspnoea 13·9 (13·4 to 14·5) 4·7 (3·9 to 5·5) <0·0001
Fatigue 13·4 (13·0 to 13·8) 3·1 (2·5 to 3·7) <0·0001
Emotion 30·6 (29·9 to 31·4) 4·2 (3·2 to 5·3) <0·0001
Mastery 18·0 (17·5 to 18·4) 2·7 (2·1 to 3·4) <0·0001
CAT 21·4 (20·8 to 22·0) –2·5 (–3·0 to –1·9) <0·0001
Data are mean (95% CI) or n (%) unless otherwise speciﬁ ed. BMI=body-mass index. FEV1=forced expiratory volume in 
1 s. MRC=Medical Research Council dyspnoea score. ISW=incremental shuttle walk. 5STS=ﬁ ve-repetition sit-to-stand. 
4MGS=4 m gait speed. SGRQ=St George’s Respirator y Questionnaire. CRQ=Chronic Respiratory Questionnaire. 
CAT=COPD Assessment Test. 
Table 1: Baseline characteristics and response to pulmonary rehabilitation (Study 1; n=565)
Slope (SE) y intercept (SE) r p value
Change in SGRQ
Total 0·18 (0·03) –1·53 (0·35) 0·32 <0·0001
Symptoms 0·06 (0·02) –2·21 (0·34) 0·14 0·0064
Activities 0·10 (0·02) –2·07 (0·33) 0·25 <0·0001
Impact 0·13 (0·02) –1·65 (0·35) 0·29 <0·0001
Change in CRQ
Total –0·15 (0·01) –0·29 (0·30) –0·46 <0·0001
Dyspnoea –0·34 (0·04) –0·90 (0·30) –0·36 <0·0001
Fatigue –0·46 (0·05) –1·03 (0·30) –0·36 <0·0001
Emotion –0·29 (0·03) –1·26 (0·28) –0·37 <0·0001
Mastery –0·40 (0·05) –1·39 (0·28) –0·33 <0·0001
Change in ISW –0·01 (0·00) –1·69 (0·35) –0·14 0·0008
Change in 4MGS –6·69 (2·17) –2·03 (0·35) –0·17 0·0022
Change in 5STS 0·03 (0·03) –2·39 (0·33) 0·06 0·40
SGRQ=St George’s Respiratory Questionnaire. CRQ=Chronic Respiratory Questionnaire. ISW=incremental shuttle walk. 
4MGS=4 m gait speed. 5STS=ﬁ ve-repetition sit-to-stand. 
Table 2: Change in COPD Assessment Test score with pulmonary rehabilitation compared with external 
anchors (Study 1; n=565)
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recruited 675 patients. For studies 2 and 3, 124 paired 
measurements were required to detect a correlation 
coeﬃ  cient above 0·3 between change in CAT and change 
in anchor with 80% power at the 0·01 signiﬁ cance level. 
We anticipated a minimum dropout of 30% on the basis 
of data from other longitudinal cohorts, therefore we 
recruited 200 patients in each study. 
We did data analyses and graphical presentations using 
SPSS (version 21) and Prism (version 5). When 
estimating MCID in change in CAT score, only data from 
participants who completed paired CAT measurements 
were included for analysis. We used the paired t test to 
compare paired measurements. We used Pearson’s 
correlation (in which the null hypothesis was deﬁ ned as 
no correlation) and linear regression to compare change 
in CAT score with other outcome measurements.
Estimation of MCID
For anchor-based estimation of MCID, predeﬁ ned criteria 
for establishing the validity of external anchors were: a 
signiﬁ cant correlation between change in CAT score and 
change in anchor, and a correlation coeﬃ  cient of more 
than 0·3 as previously recommended.20 In Study 1, 
change in CAT score with pulmonary rehabilitation was 
anchored against change in SGRQ total score, CRQ total 
score, and CRQ domain scores. For the GRCQ, we 
calculated the mean (95% CI) change in CAT score with 
pulmonary rehabilitation in those reporting feeling “a 
little better”. We did not include those reporting feeling 
“much better” because we believed that including these 
patients might lead to an overestimation of the MCID. In 
studies 2 and 3, change in CAT score was anchored 
against change in SGRQ.
In studies 1 and 2, the focus was to establish the 
minimum clinically important improvement because of 
the small numbers of patients reporting signiﬁ cant 
worsening of health status. For MCID at the individual 
patient level, we used receiver operating characteristic 
curves. The change in CAT score cutoﬀ  that best 
discriminated between patients who improved their health 
status by the established MCID in the SGRQ total score 
(–4 point change) or CRQ total score (+10 point change) 
was deﬁ ned as the MCID, with equal weighting given to 
sensitivity and speciﬁ city.10,12 For MCID at the population 
level, we used linear regression analysis to estimate change 
in CAT score corresponding to the minimum clinically 
important improvement for the SGRQ and CRQ total 
scores, and CRQ domain scores (+2·5 dyspnoea, 
+2·0 fatigue, +3·5 emotion, +2·0 mastery).10 In Study 3, 
because there were much the same numbers of patients 
showing improvement and worsening of health status, we 
applied receiver operating characteristic curves and linear 
regression to investigate both minimum clinically 
important improvement and deterioration.
For distribution-based methods, we calculated half the 
SD (0·5 SD)21 and the SE of measurement (SEM),22 given 
by the equation: SEM = SD × √ (1 – [test-retest reliability]). 
On the basis of previous data, we assumed the test-retest 
reliability of the CAT to be 0·8.2,4
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study. WD-CM made the ﬁ nal decision to 
submit for publication. 
Results
Study 1 took place between April 1, 2010, and Dec 31, 
2012. Of 675 patients with COPD referred for pulmonary 
rehabilitation, 565 (84%) completed pulmonary 
Figure 1: Association between change in CAT score and change in (A) SGRQ score and (B) CRQ score with 
pulmonary rehabilitation (Study 1)
CAT=COPD Assessment Test. SGRQ=St George’s Respiratory Questionnaire. CRQ=Chronic Respiratory Questionnaire.
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rehabilitation and had paired CAT results. The reasons 
for non-completion were exacerbation or admission to 
hospital (46 patients, 7%), poor adherence to pulmonary 
rehabilitation (29, 4%), work reasons (11, 2%), family 
illness (ten, 1%), holiday (seven, 1%), declined end of 
course assessment (four, 1%), and death (three, <1%). 
Baseline characteristics of the non-completers are 
shown in the appendix; patients who did not complete 
pulmonary rehabilitation had signiﬁ cantly worse 
baseline health status as determined by their SGRQ 
Impact and CRQ total scores. Table 1 shows the baseline 
characteristics of the completers, and the changes in 
health status and physical performance with pulmonary 
rehabilitation. Mean change in CAT with pulmonary 
rehabilitation was –2·5 (95% CI –3·0 to –1·9).
Table 2 shows the slope, y intercept, and correlation 
coeﬃ  cient between change in CAT score and change in 
other outcome measures. Only change in SGRQ total and 
change in CRQ total and CRQ domain scores correlated 
with change in CAT score with a correlation coeﬃ  cient 
greater than 0·3 (ﬁ gure 1). Figure 2 shows the receiver 
operating characteristic curves for change in CAT in 
identifying patients who improved their SGRQ and CRQ 
total scores by more than the established MCID. Both 
curves were consistent in identifying –2 as the best 
discriminating CAT change cutoﬀ  with an area under the 
curve C statistic of 0·65 for SGRQ and 0·70 for CRQ. The 
appendix shows the sensitivity and speciﬁ city for 
alternative estimates of the minimum clinically important 
improvement in CAT score.
With linear regression, by use of a change in CRQ total 
score of +10 as the cutoﬀ  for minimum clinically 
important improvement, the estimated minimum 
clinically important improvement in CAT score was 
–1·8 (95% CI –2·6 to –1·0). By use of the established 
MCID for the CRQ domains as cutoﬀ s, the estimates for 
minimum clinically important improvement in CAT 
score were –1·7 (95% CI –2·5 to –1·0) for dyspnoea, 
–2·0 (–2·7 to –1·2) for fatigue, –2·3 (–3·0 to –1·5) for 
emotion, and –2·2 (–2·9 to –1·5) for mastery. With 
SGRQ total change of –4 as the cutoﬀ , the estimated 
minimum clinically important improvement for CAT 
score was –2·3 (95% CI –2·7 to –1·8). There were few 
patients reporting signiﬁ cant worsening in health status 
Figure 2: Receiver operator characteristic curves using a change in COPD Assessment Test score of –2 to 
best predict achievement of minimum clinically important improvement in (A) SGRQ score and (B) CRQ 
score (Study 1)
ΔSGRQ=change in St George’s Respiratory Questionnaire score. ΔCRQ=change in Chronic Respiratory 
Questionnaire score. AUC=area under the curve C statistic. 
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discharge
Change at 90 days p value
Mean age (years 
[SD]) 
71 (11) ·· ··
Sex
Men 88 (60%) ·· ··
Women 59 (40%) ·· ··
Mean BMI (kg/m² 
[SD]) 
27·1 (5·2) ·· ··
FEV1 (% predicted) 42 (39 to 46) 5·7 (1·7 to 9·8) 0·19
MRC 3·9 (3·7 to 4·1) –0·6 (–0·8 to –0·4) <0·0001
SGRQ
Total 57·1 (54·6 to 59·6) –6·8 (–8·8 to –4·9) <0·0001
Symptoms 67·3 (64·2 to 70·3) –0·3 (–2·9 to 2·3) 0·84
Activities 74·3 (70·9 to 77·7) –6·0 (–8·8 to –3·1) <0·0001
Impact 44·1 (41·4 to 46·8) –9·5 (–11·8 to –7·2) <0·0001
4MGS (m s–1) 0·66 (0·62 to 0·70) 0·22 (0·18 to 0·26) <0·0001
CAT 23·5 (22·3 to 24·8) –3·0 (–4·4 to –1·6) <0·0001
Data are mean (95% CI) or n (%) unless otherwise speciﬁ ed. BMI=body-mass index. 
FEV1=Forced expiratory volume in 1 s. MRC=Medical Research Council dyspnoea 
score. SGRQ=St George’s Respiratory Questionnaire. 4MGS=4 m gait speed. 
CAT=COPD Assessmen t Test. 
Table 3: Baseline characteristics (at hospital discharge) of patients with 
acute exacerbation of COPD and change over 3 months (Study 2; n=147)
See Online for appendix
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(ﬁ gure 1); comparison of the slopes of CAT score against 
CRQ and SGRQ scores in patients who improved and 
those who deteriorated showed no signiﬁ cant diﬀ erence 
(ANCOVA p=0·67 and p=0·99, respectively).
With the GRCQ, 299 of 565 (53%) patients reported 
feeling much better, 209 (37%) patients reported feeling a 
little better, 40 (7%) patients reported no change, and 
17 (3%) patients reported feeling a little or much worse. 
The mean change in CAT score in those reporting feeling 
“a little better” after pulmonary rehabilitation was 
–1·6 (95% CI –2·6 to –0·8). For those feeling “much 
better”, the mean change in CAT score was 
–3·2 (95% CI –4·0 to –2·5).
With distribution-based methods, the estimate for 
signiﬁ cant improvement in CAT score using 0·5 SD was 
–3·8 and using SEM was –3·3.
Study 2 took place between Nov 16, 2011, and Dec 31, 
2012. Of 200 patients with acute exacerbations of COPD 
recruited, 147 (74%) had paired CAT measurements. 
Reasons for dropout were death (14 patients, 7%), declined 
attendance (26, 13%), acutely unwell in hospital (ten, 5%), 
and moved out of area (three, 2%). The mean duration 
between baseline (discharge from hospital) and follow-up 
measurement was 90·2 days (SD 7·7; range 79–102). The 
appendix shows baseline characteristics of patients who 
did not attend follow-up; baseline characteristics of those 
who attended follow-up and those who did not attend did 
not diﬀ er. Table 3 shows clinical characteristics of this 
group and the change in outcomes after hospital dis-
charge. Mean CAT score at hospital discharge (23·5 
[95% CI 22·3–24·8]) was signiﬁ cantly higher than baseline 
CAT score in patients referred for pulmonary rehabilitation 
in Study 1 (21·4 [20·8 to 22·0]) and stable outpatients in 
Study 3 (20·1 [19·1 to 21·2]; ANOVA p=0·0002).
Mean change in CAT score from hospital discharge to 
3 months after discharge was –3·0 (95% CI –4·4 to –1·6). 
Change in CAT score correlated signiﬁ cantly with 
change in SGRQ (r=0·47; p<0·0001; ﬁ gure 3) and 
change in FEV1 (r=–0·26; p=0·0021), but not change in 
4 m gait speed (r=–0·10; p=0·24). By use of receiver 
operating characteristic curves, a –2 change in CAT 
score best discriminated patients who improved by the 
MCID or more in SGRQ (n=84) with an area under the 
curve C statistic of 0·66. Sensitivity and speciﬁ city data 
for alternative estimates are in the appendix. Linear 
regression analysis, using an SGRQ change of –4 as the 
cutoﬀ , estimated the minimum clinically important 
improvement of the CAT as –2·8 (95% CI –3·7 to –1·9). 
The slopes of CAT against SGRQ in patients who 
improved and in those who deteriorated were not 
signiﬁ cantly diﬀ erent (ANCOVA p=0·21).
With distribution-based methods, the estimate for 
signiﬁ cant improvement in CAT score using 0·5 SD was 
–3·7 and using SEM was –3·3.
Study 3 recruited between Jan 1, 2012, and Aug 31, 
2012. Of 200 stable patients recruited, 164 (82%) returned 
for measurements 12 months later. Reasons for dropout 
included: death (six patients, 3%), current admission to 
hospital for exacerbation (seven, 4%), current admission 
to hospital for another reason (four, 2%), declined (ten, 
5%), unable to contact (six, 3%),  and moved out of area 
(three, 2%). The mean duration between baseline and 
follow-up measurement was 364·6 days (SD 20·7, range 
332–401 days). The appendix shows baseline characteristics 
of patients who did not attend follow-up; patients who did 
not attend follow-up were younger and had better CAT 
scores than those who attended follow-up. Table 4 shows 
clinical characteristics of this cohort and change in FEV1, 
incremental shuttle walk, 4 m gait speed, CAT, and 
SGRQ with time. There was no signiﬁ cant change in 
CAT over time, but change in CAT correlated signiﬁ cantly 
with change in SGRQ (r=0·36; p<0·0001; ﬁ gure 4), 
Figure 3: Association between CAT score and change in SGRQ score at hospital discharge for acute 
exacerbation of COPD to 90 days after discharge (Study 2)
CAT=COPD Assessment Test. SGRQ=St George’s Respiratory Questionnaire.
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Mean age (years [SD]) 70 (8) ·· ··
FEV1 (% predicted) 47·6 (44·4 to 50·8) –1·7 (–6·9 to 3·4) 0·51
MRC 3·1 (3·0 to 3·3) 0·1 (–0·1 to 0·2) 0·35
ISW (m) 227 (208 to 247) –15 (–43 to 12) 0·28
4MGS (m s–1) 0·92 (0·89 to 0·95) –0·04 (–0·06 to –0·02) <0·0001
SGRQ
Total 50·6 (48·0 to 53·1) –0·3 (–4·4 to 3·9) 0·91
Symptoms 63·9 (60·9 to 67·0) –2·5 (–7·4 to 2·4) 0·32
Activities 68·7 (65·4 to 72·0) 1·3 (–3·8 to 6·3) 0·62
Impact 35·9 (33·1 to 38·7) 0·0 (–4·3 to 4·3) 0·99
CAT 20·1 (19·1 to 21·2) 0·6 (–0·4 to 1·5) 0·25
Data are mean (95% CI) unless otherwise speciﬁ ed. FEV1=forced expiratory volume in 1 s. MRC=Medical Research Council 
dyspnoea score. ISW=incremental shuttle walk. SGRQ=St George’s Respiratory Questionnaire. 4MGS=4 m gait speed. 
CAT=COPD Assessment Test. 
Table 4: Baseline characteristics in patients with stable COPD and change over 12 months (Study 3; n=164)
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incremental shuttle walk (r=–0·25; p=0·0005), and 4 m 
gait speed (r=–0·18; p=0·0142). For those who improved 
their SGRQ (n=64), the receiver operating characteristic 
curve showed that a –1 point change in CAT score was 
the best discriminant with an area under the curve C 
statistic of 0·66, and that a +1 point change in CAT score 
best identiﬁ ed those who had a clinically signiﬁ cant 
worsening in health status as measured by the SGRQ 
(n=51) with an area under the curve C statistic of 0·69. 
With SGRQ change of –4 as an anchor, linear regression 
analysis estimated the minimum important improvement 
in CAT score as –1·2 (95% CI –2·5 to –0·0). The slopes 
of CAT score against SGRQ score in patients who 
improved and those who deteriorated were not 
signiﬁ cantly diﬀ erent (ANCOVA p=0·20).
With distribution-based methods, the estimate for 
signiﬁ cant improvement in the CAT score using 0·5 SD 
was 3·8 and using SEM was 3·4. Table 5 summarises all 
estimates for the MCID for the CAT.
Discussion
Our studies show that the CAT is responsive to change 
after pulmonary rehabilitation and recovery from 
hospital admission for acute exacerbation of COPD, and 
that change in CAT correlates signiﬁ cantly with change 
in other health status measures and physical 
performance measures. Furthermore, as far as we are 
aware, these studies are the ﬁ rst to prospectively and 
purposively estimate the MCID for the CAT. With 
anchors measuring similar constructs in diﬀ erent 
cohorts, the estimates for the minimum important 
improvement in CAT score ranged from –1·2 to –2·8 
with –2 being the most consistent estimate from 
sensitivity and speciﬁ city analyses.
Health status is recommended as an essential outcome 
measure by pulmonary rehabilitation guidelines.23 As far 
as we are aware, Study 1 was the largest study so far to 
use the CAT during pulmonary rehabilitation (panel). We 
showed longitudinal validity of the CAT by identifying 
signiﬁ cant correlations between change in CAT and 
change in SGRQ, CRQ, and physical performance 
measures. We recorded a mean change in CAT score 
of –2·5 with an 8 week outpatient pulmonary 
rehabilitation programme, in line with previous studies 
from the UK and the USA and Canada.3,7 The CAT has 
also been studied in an unselected chronic respiratory 
disease population undergoing pulmonary rehabilitation, 
with 110 non-COPD patients showing a mean CAT 
change of –2·1, much the same as the mean change 
measured in patients with COPD.19
Several studies have used the CAT as a measure of 
health status during hospital and community-based 
treatment of acute exacerbations of COPD, showing 
changes in CAT ranging from –1·4 to –9·9.4,5 Study 2 
focused exclusively on recovery of the CAT score after 
admission to hospital, with the baseline CAT measured 
on the day of hospital discharge. The recorded mean 
Figure 4: Association between change in CAT score and change in SGRQ score over 12 months in stable 
patients with COPD (Study 3)
CAT=COPD Assessment Test. SGRQ=St George’s Respiratory Questionnaire.
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Study 1: Pulmonary rehabilitation
ROC SGRQ –2
ROC CRQ –2
Linear regression SGRQ –2·3
Linear regression CRQ –1·8
Linear regression CRQ-D –1·7
Linear regression CRQ-F –2·0
Linear regression CRQ-E –2·3
Linear regression CRQ-M –2·2
Linear regression GRCQ* –1·6
Distribution 0·5 SD –3·8
Distribution SEM –3·3
Study 2: At discharge from hospital
ROC SGRQ –2
Linear regression SGRQ –2·8
Distribution 0·5 SD –3·7
Distribution SEM –3·3
Study 3: Longitudinal
ROC SGRQ –1
Linear regression SGRQ –1·2
Distribution 0·5 SD –3·8
Distribution SEM –3·4
MCID=minimum clinically important diﬀ erence. ROC=receiver operating 
characteristic curves. SGRQ=St George’s Respiratory Questionnaire. CRQ=Chronic 
Respiratory Questionnaire total score. CRQ-D=dyspnoea domain. CRQ-F=fatigue 
domain. CRQ-E=emotion domain. CRQ-M=mastery domain. GRCQ=Global Rating 
of Change Questionnaire. 0·5 SD=half SD. SEM=SE of measurement. *In patients 
feeling “a little better”.
Table 5: Anchor-based and distribution-based estimates of the MCID of 
the CAT in the three studies
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change in CAT was –3·0, and this outcome correlated 
signiﬁ cantly with change in SGRQ (r=0·47). This ﬁ nding 
could have implications when designing clinical 
intervention trials in the period after admission to 
hospital, particularly with regard to sample size 
calculation.
Until now, there have been few data regarding 
longitudinal change in CAT with time. In the original 
description of the CAT, test-retest reproducibility over 
7 days was good (intraclass correlation coeﬃ  cient 0·8), 
while in stable patients over 4 weeks, the CAT showed a 
test-retest intraclass correlation coeﬃ  cient of 0·83.2,4 
Over a 6 month period, Dodd and colleagues6 showed an 
increase in CAT from 19·2 to 20·7, although importantly, 
baseline measurements were recorded immediately after 
completion of a pulmonary rehabilitation programme. 
We recorded paired measurements 12 months apart. Our 
prespeciﬁ ed hypothesis that health status would 
deteriorate signiﬁ cantly over 12 months (ie, increase in 
CAT score) was not supported by our data, although 
deteriorating health status, including death, was a reason 
for loss to follow-up. Although the 12 month recall rate 
was good (higher than 80%), there was likely to be an 
element of selection bias in that paired CAT scores were 
not obtained in those who had died or were receiving 
inpatient treatment at the recall timepoint. Nevertheless, 
it was reassuring to show that change in the CAT 
correlated signiﬁ cantly with change in SGRQ and 
physical performance measures over 12 months.
The determination of the MCID remains controversial 
with no ﬁ rm consensus, but is important in the validation 
of clinical instruments and the assessment of clinical 
studies. Two main approaches are generally used: anchor 
and distribution-based methods. Anchor-based methods 
rely on comparison of the change in outcome of interest 
with another outcome measure of change, known as the 
anchor or external criterion. However, this comparison is 
only relevant if there is an established association 
between the outcome of interest and the anchor. No 
consensus exists regarding the threshold strength of the 
association: some investigators have suggested an 
arbitrary minimum correlation coeﬃ  cient of greater 
than 0·50, although others have suggested 0·30.11,20 
Although cross-sectional studies have shown strong 
correlations of the CAT and SGRQ, with four units on 
the SGRQ corresponding to 1·6 on the CAT, this 
association might diﬀ er when assessing change in these 
instruments.26 The MCID is most useful for clinicians or 
researchers in the “change” setting, and therefore we 
made great eﬀ orts to assess change in CAT in three 
independent cohorts, including longitudinal follow-up. 
The candidate anchors with strongest correlations were 
COPD-speciﬁ c health status questionnaires (CRQ and 
SGRQ), presumably because these instruments measure 
similar constructs to the CAT, with correlation coeﬃ  cients 
ranging from 0·32 to 0·47. Previous guidance has 
recommended the use of several approaches and 
triangulation of methods.20 We used several anchors, 
adopted diﬀ erent methods of anchor-based estimations 
(linear regression analysis, sensitivity and speciﬁ city 
analysis using receiver operating characteristic curves), 
and presented change in CAT in three diﬀ erent clinical 
scenarios to provide clinical context.
The estimates of the MCID of the CAT were consistent 
across diﬀ erent cohorts in diﬀ erent scenarios over 
diﬀ erent timeframes (table 5), providing some degree of 
corroboration and credibility, although the correlations 
with the external anchors were only moderate and 
caution is needed in the interpretation. At the individual 
level (the CAT score permits only integers), the ROC 
analysis and the anchor responses to the GRCQ 
estimated the MCID to be –2. From the linear regression 
analysis, the population-level MCID estimates ranged 
from –1·2 to –2·8, with the mean of these estimates 
being –2·0. Therefore, both the population-level estimate 
(used to assess group eﬀ ects of treatments or diﬀ erences 
between populations) and the individual patient-level 
estimate (used for responder analysis) was –2.
Anchor-based methods to estimate MCID are often 
preferred to distribution-based approaches because they 
take into account patient-reported beneﬁ t or deterioration. 
However, there are limitations. As mentioned previously, 
anchor-derived estimates are only valid if the outcome of 
interest correlates with the anchor. Any patient-reported 
outcome recorded before and after a period of time is also 
subject to recall bias. Anchors are designed to detect 
change in outcome but rarely take into account costs to the 
Panel: Research in context
Systematic review
We searched PubMed for studies in English focusing on estimates of the minimum 
clinically important diﬀ erence (MCID) of the COPD Assessment Test (CAT) from 
inception, to Oct 21, 2013. We used the terms “MID” or “minimal important diﬀ erence” 
or “minimum important diﬀ erence” or “MCID” or “minimal clinically important 
diﬀ erence” and “CAT” or “COPD Assessment Test” or “Chronic Obstructive Pulmonary 
Disease Assessment Test”. We identiﬁ ed three studies7,24,25 that provided estimates of the 
MCID of the CAT, although through retrospective opportunistic post-hoc analyses. 
These studies looked at improvement in stable populations using only one 
methodological approach for estimation; the resulting estimates ranged from a 
–1·3 to –3·76 point change.
Interpretation
As far as we are aware, this is the ﬁ rst report to provide prospective data to estimate the 
MCID of the CAT.  Our studies provide 19 separate estimates of the MCID using both 
distribution-based and anchor-based methods, from three separate clinically relevant 
cohorts, including stable patients having pulmonary rehabilitation and longitudinal 
follow-up, and also in those recovering from exacerbation. To our knowledge, Study 1 is 
the largest study using the CAT in pulmonary rehabilitation. Our ﬁ ndings suggest that a 
decrease in CAT of 2 points is the most reliable estimate of the MCID at the individual 
and population level.  This estimate will allow clinicians to interpret clinically important 
change in individual patients, and help researchers with sample size calculations and the 
interpretation of CAT data in response to intervention studies.
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patient, for example side-eﬀ ects of therapy. Another 
limitation is that changes in an outcome measure might 
be associated with baseline level. Potential reasons for this 
association include so-called ﬂ oor and ceiling eﬀ ects. The 
CAT score ranges from 0 to 40 with a decrease in score 
showing improvement in health status. At extreme values 
(eg, a baseline CAT of 0), the instrument cannot detect an 
improvement in health status. Similarly, if the baseline 
CAT is 40, there is no room for further worsening in health 
status. Although we used three independent cohorts of 
patients with COPD, with varying baseline mean values, 
these were generally recruited from a secondary care 
setting. The present studies cannot address whether our 
estimates of MCID for the CAT hold true in populations at 
extremes of the health spectrum (for example, community-
dwelling asymptomatic patients with COPD, or highly 
symptomatic patients receiving palliative care).
To provide a comprehensive approach, we also used 
distribution-based methods to estimate the MCID of the 
CAT. Distribution-based approaches use statistical 
methods, and are based on the distribution of the cohort 
and the reliability of the measure; as such they do not take 
into account whether the recorded change is important 
from the patient’s perspective. Previous investigators 
have noted that 0·5 SD and the SEM might approximate 
the MCID in some patient-reported outcome measures,21,22 
although other measures have also been described 
including 1·96 SEM and minimum detectable change; 
depending on which distribution-based approach is used, 
a range of diﬀ erent estimates of the MCID can be 
generated which might signiﬁ cantly limit their 
interpretation.27 Another speciﬁ c limitation to the present 
studies was that the test-retest reliability of the CAT was 
assumed on the basis of previous studies of much shorter 
duration. Our estimates of the MCID for the CAT, using 
0·5 SD and SEM, were consistent across the three clinical 
scenarios, suggesting that the distributions of our three 
cohorts were much the same. However, it was also 
noticeable that the distribution-based methods 
consistently estimated the MCID to be greater than the 
anchor-based estimates, suggesting that the CAT had a 
wide distribution in our cohorts. This situation is not 
unique in patients with COPD. For example, Puhan and 
colleagues28 showed that the MCID for maximal cycle 
exercise capacity ranged from 2·2 W to 3·3 W, whereas 
distribution-based estimates were 5·3–5·5 W.28
Although we provide data from both approaches we 
have chosen to place greater emphasis on the anchor-
based estimates for two reasons. First, although 
distribution-based estimates provide supportive infor-
mation regarding a signiﬁ cant change, they do not 
provide a direct measure of minimum clinical importance, 
a view shared by other researchers.28,29 Second, the MCIDs 
estimated by distribution-based methods were greater 
than the mean change identiﬁ ed after pulmonary 
rehabilitation, widely accepted as a highly eﬀ ective 
intervention that signiﬁ cantly improves health-related 
quality of life in COPD, and the mean change identiﬁ ed 
during recovery after admission to hospital for severe 
exacerbation of COPD. In view of these clinical contexts, 
we believe the data derived from distribution-based 
methods provide information about clinical signiﬁ cance 
but might overestimate the true MCID.
In the present studies, our focus was on establishing 
the minimum clinically important improvement. In 
studies 1 and 2, the number of patients with improving 
health status far outweighed those who had worsening 
health status (90% vs 3% according to the GRCQ), and 
we did not report estimates of minimum important 
clinical deterioration for fear of imprecision. We 
believe that the magnitude of the minimum clinically 
important deterioration is likely to be much the same 
as for improvement. For example, when we compared 
the linear regression slopes of those who improved 
and deteriorated according to their anchor, we 
identiﬁ ed no signiﬁ cant diﬀ erence. In Study 3, in 
which there were more equivalent numbers of patients 
improving and worsening their health status, the 
receiver operating characteristic curves estimated 
similar magnitude cutoﬀ s. Further studies focusing 
on worsening health status are needed to conﬁ rm 
whether patients perceive size of deterioration 
diﬀ erently to size of improvement.
The main aim of the present studies was to estimate the 
MCID in change in CAT, and hence paired measurements 
were used for the analyses. In all three studies, there were 
missing data (usually because of exacerbation) and it 
could be argued that these missing data might bias our 
estimates of the MCID. If a patient deteriorated because 
of exacerbation or admission to hospital, we would expect 
not only the CAT to worsen but also the external anchors. 
Because there was no diﬀ erence in the slopes of change 
in patients who improved compared with those who 
deteriorated, we do not believe that missing data were a 
signiﬁ cant source of bias in our estimates of the MCID 
for the CAT.
In summary, the present studies show that the CAT is 
responsive to the eﬀ ects of pulmonary rehabilitation and 
recovery from admission to hospital for acute exacerbation 
of COPD. By use of various health status and global rating 
of change questionnaires as external anchors, we estimate 
the minimum important improvement of the CAT to be a 
two point decrease at both the individual and population 
level. This information could be useful in the clinical 
interpretation of CAT data, particularly in response to 
intervention studies.
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